A Phase 3 interventional study of Semaglutide and Placebo (semaglutide) in Overweight, Obesity and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 33 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-29.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
How we know · 7 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 144 studies testing semaglutide in Obesity — 69 open to participants now, 78 under way, 14 of them phase 3. Semaglutide · Obesity.
Among the 144 studies testing semaglutide in Obesity, this one is the 25th largest by enrollment, is one of 4 that started in 2020, is one of 42 in phase 3, and was the 23rd registered.
11,560 studies on the registry are indexed under Obesity; 2,055 are open to participants now.
Browse Obesity studies →69 of the 144 studies testing semaglutide in Obesity are open now, in 12 countries. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 18+ · Men only
McMaster University · Sites in Canada
Ages 18–60
Alain Dagher · Sites in Canada
Ages 35–55 · Healthy volunteers
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 12–18
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18–65
By country, each count listing its studies:
Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 1,346 Obesity studies recruiting now, 379 (28%) set no upper age limit and 863 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, semaglutide is the treatment under test here. Read study by study →
144 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 25 · Phase 3 46 · Phase 4 40
First in 2014; this study’s year is marked. 4 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 375 is above the median of 67 across 9,036 interventional studies indexed under Obesity.
Median enrollment 100 across the 144 interventional studies. Of the 60 that completed or were terminated, 35 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
49 of 144 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
210 studies in Obesity by Novo Nordisk A/S: 51 open now, 69 under way, 26 of them phase 3. Of 138 finished, 39 (28%) have results posted.
Among the 210 studies in Obesity by Novo Nordisk A/S, this one is the 45th largest by enrollment of the 169 interventional ones that give a count, is one of 7 that started in 2020, is one of 62 in phase 3, and was the 68th registered.
Novo Nordisk A/S’s Obesity studies by the year they started, since 2007.
22 of the studies testing semaglutide in Obesity that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07740291Texas Tech UniversityTirzepatide Impact Assessment Study | 2026-11-23 |
| NCT07430059Vivani Medical, IncSafety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant | 2026-12 |
| NCT07225816Novo Nordisk A/SExamination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) | 2026-12-13 |
| NCT06546384Insel Gruppe AG, University Hospital BernGLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease | 2026-12-31 |
| NCT05173714Srinvasan BeddhuSit Less, Interact and Move More (SLIMM) 2 Study | 2026-12-31 |
Add all 22 to your calendar (.ics) → With an account.
Among the 144 studies testing semaglutide in Obesity, from their registry updates:
Among Novo Nordisk A/S’s 210 in Obesity:
This tab as a report to print or save as PDF → With an account.
This study will look at the change in body weight from the start to the end of the study. The purpose of the study is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy" medicine. In addition to taking the medicine participants will have talks with study staff about healthy food choices, how to be more physically active and what else they can do to lose weight. Participants will either get semaglutide or "dummy medicine" - which treatment is decided by chance. Participants will need to take 1 injection once a week. The study medicine is injected with a thin needle in a skinfold in the stomach, thigh or upper arm.• The study will last for about 1 year. Participants will have 11 clinic visits and 8 phone calls with the study doctor. Participants will have 3 clinic visits where they cannot eat and drink (water is allowed) for up to 8 hours before the visit and 1 clinic visit where they cannot eat and drink for up to 2 hours before the visit. (4 visits and 1 visit, respectively, if they have type 2 diabetes (T2D)). Participants will have 4 clinic visits where they will have blood samples taken. (5 visits if they have T2D). For China: Participants will have 9 clinic visits where they will have blood samples taken. Women cannot take part if pregnant, breast-feeding or planning to become pregnant during the study period.
11,560 studies on the registry are indexed under Obesity; 2,055 are open to participants now.
This study's enrollment of 375 is above the median of 67 across 9,036 interventional studies indexed under Obesity.
Browse Obesity studies →Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For subjects without T2D at screening:
For subjects with T2D at screening:
Exclusion Criteria:
For subjects without T2D at screening:
- equal to or above 6.5% (48 mmol/mol) as measured by the central laboratory at screening
For subjects with T2D at screening :
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Once-weekly injections of gradually increased doses of semaglutide
Drug: Semaglutide
Once-weekly injections of gradually increased doses of semaglutide placebo
Drug: Placebo (semaglutide)
Semaglutide administered subcutaneously (s.c., under the skin) as well as diet and physical activity counselling for 44 weeks. Doses gradually increased to 2.4 mg
Semaglutide placebo administered s.c. as an adjunct to a reduced-calorie diet and increased physical activity regimen for 44 weeks
Change From Baseline in Body Weight (Percentage [%])
Change from baseline at week 0 to week 44 in body weight (%) is presented.The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
Time frame: Baseline (week 0), week 44
Number of Participants Who Achieved Body Weight Reduction Greater Than or Equal (>=) to 5% (Yes/No)
Number of participants who achieved \>=5% weight reduction at week 44 for in-trial observation period is presented.In the reported data, 'Yes' infers the number of participants who have achieved greater than or equal to 5% weight reduction, whereas 'No' infers the number of participants who have not achieved greater than or equal to 5% weight reduction. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
Time frame: At week 44
Number of Participants Who Achieved Body Weight Reduction Greater Than or Equal (>=) to 10% (Yes/No)
Number of participants who achieved \>=10% weight reduction at week 44 for in-trial observation period is presented. In the reported data, 'Yes' infers the number of participants who have achieved greater than or equal to 10% weight reduction, whereas 'No' infers the number of participants who have not achieved greater than or equal to 10% weight reduction. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
Time frame: At week 44
Number of Participants Who Achieved Body Weight Reduction Greater Than or Equal (>=) to 15% (Yes/No)
Number of participants who achieved \>=15% weight reduction at week 44 for in-trial observation period is presented. In the reported data, 'Yes' infers the number of participants who have achieved greater than or equal to 15% weight reduction, whereas 'No' infers the number of participants who have not achieved greater than or equal to 15% weight reduction. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
Time frame: At week 44
Change From Baseline in Waist Circumference
Change in waist circumference from baseline (week 0) to week 44 is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomization (week 0) to last trial-related participant-site contact (week 51).
Time frame: Baseline (week 0), week 44
Change From Baseline in Body Weight (Kilogram [kg])
Change in body weight from baseline (week 0) to week 44 is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
Time frame: Baseline (week 0), week 44
Change From Baseline in Body Mass Index (BMI)
Change in BMI from baseline (week 0) to week 44 is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
Time frame: Baseline (week 0), week 44
Number of Participants Who Achieved Body Weight Reduction Greater Than or Equal (>=) to 20% (Yes/No)
Number of participants who achieved \>=20% weight reduction at week 44 for in-trial observation period is presented. In the reported data, 'Yes' infers the number of participants who have achieved greater than or equal to 20% weight reduction, whereas 'No' infers the number of participants who have not achieved greater than or equal to 20% weight reduction. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
Time frame: At week 44
Change From Baseline in Systolic Blood Pressure
Change in systolic blood pressure from baseline (week 0) to week 44 is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
Time frame: Baseline (week 0), week 44
Change From Baseline in Short Form-36 (SF-36) - Physical Functioning Score
SF-36 is a 36-item participants-reported survey of participants health that measures the partici-pants overall health-related quality of life (HRQoL). SF-36 questionnaire measured 8 domains of functional health and well-being as well as 2 component summary scores (physical component summary and mental component summary). This outcome measure shows results for 'physical functioning domain'. Physical function domain score ranges from 0 to 100, with higher values indicating better functional health and well-being. Change from baseline (week 0) in the domain scores were evaluated at week 44. These outcome measures were evaluated based on data from in-trial observation period which is the uninterrupted time interval from (week 0) to (week 51).
Time frame: Baseline (week 0), week 44
Change From Baseline in Impact of Weight on Quality of Life-Lite for Clinical Trials (IWQOL-Lite for CT) - Physical Function Domain (5-items) Score
The Impact of Weight on Quality of Life Clinical Trials Version (IWQOL-Lite-CT) is designed to assess the impact of changes in weight on participants quality of life within the context of clinical trials. IWQOL-Lite-CT is a 20-item questionnaire-based instrument used to assess the impact of body weight changes on participants overall health-related quality of life (HRQoL). All IWQOL-Lite-CT composite and physical function domain scores range from 0 to 100, with higher scores reflecting better levels of functioning. This outcome measure shows results for 'physical function domain'. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomization (week 0) to last trial-related participant-site contact (week 51).
Time frame: Baseline (week 0), week 44
Change From Baseline in Glycosylated Haemoglobin (HbA1c) (Percentage [%])
Change in glycosylated haemoglobin (HbA1c) (%) from baseline (week 0) to week 44 is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
Time frame: Baseline (week 0), week 44
Change From Baseline in HbA1c (Millimoles Per Mole [mmol/Mol])
Change in HbA1c (mmol/mol) from baseline (week 0) to week 44 is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
Time frame: Baseline (week 0), week 44
Change From Baseline in Fasting Plasma Glucose (FPG) (Milligrams Per Deciliter [mg/dL])
Change in fasting plasma glucose (mg/dL) from baseline (week 0) to week 44 is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
Time frame: Baseline (week 0), week 44
Change From Baseline in FPG (Millimoles Per Liter [mmol/L])
Change in FPG (mmol/L) from baseline (week 0) to week 44 is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
Time frame: Baseline (week 0), week 44
Change From Baseline in Fasting Serum Insulin: Ratio to Baseline
Change in fasting serum insulin measured as milli-international units per milliliter (mIU/mL) from baseline (week 0) to week 44 is presented as ratio to baseline. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
Time frame: Baseline (week 0), week 44
Change From Baseline in Diastolic Blood Pressure
Change in diastolic blood pressure from baseline (week 0) to week 44 is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
Time frame: Baseline (week 0), week 44
Change From Baseline in Total Cholesterol: Ratio to Baseline
Change in total cholesterol measured as milligrams per deciliter (mg/dL) from baseline (week 0) to week 44 is presented as ratio to baseline. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
Time frame: Baseline (week 0), week 44
Change From Baseline in High-Density Lipoproteins (HDL)-Ratio to Baseline
Change in HDL measured as milligrams per deciliter (mg/dL) from baseline (week 0) to week 44 is presented as ratio to baseline. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
Time frame: Baseline (week 0), week 44
Change From Baseline in Low-Density Lipoproteins (LDL)-Ratio to Baseline
Change in LDL measured as milligrams per deciliter (mg/dL) from baseline (week 0) to week 44 is presented as ratio to baseline. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
Time frame: Baseline (week 0), week 44
Change From Baseline in Very Low-Density Lipoproteins (VLDL)-Ratio to Baseline
Change in VLDL measured as milligrams per deciliter (mg/dL) from baseline (week 0) to week 44 is presented as ratio to baseline. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
Time frame: Baseline (week 0), week 44
Change From Baseline in Free Fatty Acids-Ratio to Baseline
Change in free fatty acids measured as milligrams per deciliter (mg/dL) from baseline (week 0) to week 44 is presented as ratio to baseline. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
Time frame: Baseline (week 0), week 44
Change From Baseline in Triglycerides-Ratio to Baseline
Change in triglycerides measured as milligrams per deciliter (mg/dL) from baseline (week 0) to week 44 is presented as ratio to baseline. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
Time frame: Baseline (week 0), week 44
Change From Baseline in SF-36 All Domains (Except Physical Functioning) and 2 Component Summary Scores
SF-36 is a 36-item participant-reported survey of health that measures the overall HRQoL. SF-36 questionnaire measured 8 domains of functional health and well-being as well as 2 component summary scores (physical and mental component summary). This outcome measure shows results for all domains (except physical functioning) and 2 component summary scores. The score ranges from 0 to 100, with higher values indicating better functional health and well-being. Change from baseline week 0 in domain and component summary scores were evaluated at week 44 based on data from in-trial observation period which is uninterrupted time interval from (week 0) to (week 51).
Time frame: Baseline (week 0), week 44
Change From Baseline in IWQOL-Lite for Physical Domain Score, Psychological Domain Score and Total Score
The Impact of Weight on Quality of Life Clinical Trials Version (IWQOL-Lite-CT) is designed to assess the impact of changes in weight on participants quality of life within the context of clinical trials. IWQOL-Lite-CT is a 20-item questionnaire-based instrument used to assess the impact of body weight changes on participants overall health-related quality of life (HRQoL). All IWQOL-Lite-CT composite scores for physical domain score, psychosocial domain score and total score ranges from 0 to 100, with higher scores reflecting better levels of functioning. This outcome measure shows results for 'physical and psychosocial domains, and for total'. The outcome measure was evaluated based on the data from in-trial observation period which is the uninterrupted time interval from start of randomization (week 0) to last trial-related participant-site contact (week 51).
Time frame: Baseline (week 0), week 44
Number of Participants Who Achieved Responder Definition Value for SF-36 Physical Functioning Score (Yes/No)
The number of participants experiencing a meaningful within participant improvement in SF-36 Physical function after 44 weeks was determined based on 3.7 threshold. The threshold of 3.7 is specific for overweight or obese population included in the study and calculated using participant global rating anchor questionnaires to reflect participants own perspective based on Food and Drug Administration (FDA) recommendations. In the reported data, "Yes" infers the number of participants who have achieved an improvement in score greater than or equal to the threshold and "No" infers number of participants who have not achieved an improvement in score greater than or equal to the threshold. The outcome measure was evaluated based on in-trial observation period which is the uninterrupted time interval from start of randomization (week 0) to last trial-related participant-site contact (week 51).
Time frame: At week 44
Number of Participants Who Achieved Responder Definition Value For IWQoL-Lite for CT Physical Function (5-items) Score (Yes/No)
The number of participants experiencing a meaningful within participant improvement in IWQOL-Lite-CT physical function after 44 weeks was determined based on thresholds of 14.6. The threshold of 14.6 is specific for the population with overweight or obesity included in the study and calculated using patient global rating anchor questionnaires to reflect participants own perspective based on FDA recommendations. In the reported data, "Yes" infers the number of participants who have achieved an improvement in score greater than or equal to the threshold and "No" infers the number of participants who have not achieved an improvement in score greater than or equal to the threshold. The outcome measure was evaluated based on in-trial observation period which is the uninterrupted time interval from start of randomization (week 0) to last trial-related participant-site contact (week 51).
Time frame: At week 44
Number of Participants With Type 2 Diabetes (T2D) Who Achieved HbA1c Less Than (<) 7.0 Percent (%) (53 mmol/Mol)
Number of participants with T2D who achieved HbA1c \< 7% (53 mmol/mol) at week 44 is presented. In the reported data, "Yes" infers the number of participants who have achieved HbA1c values less than the 7% and "No" infers the number of participants who have not achieved HbA1c values less than the 7%. The outcome measure was evaluated based on the data from in-trial observation period which was defined as the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
Time frame: At week 44
Number of Participants With T2D Who Achieved HbA1c Less Than or Equal to (<=) 6.5% (48 mmol/Mol)
Number of participants with T2D who achieved HbA1c \<= 6.5% (48 mmol/mol) at week 44 is presented. In the reported data, "Yes" infers the number of participants who have achieved HbA1c values less than or equal to 6.5% and "No" infers the number of participants who have not achieved HbA1c values less than or equal to 6.5%. The outcome measure was evaluated based on the data from in-trial observation period which was defined as the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
Time frame: At week 44
Change From Baseline in Glycaemic Category (Normo-Glycaemia, Pre-Diabetes, T2D) in Participants With no T2D at Baseline
Change from baseline in number of participants in glycaemic categories (normo-glycaemia, pre-diabetes and type 2 diabetes) at baseline (week 0) to week 44 are presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
Time frame: Baseline (week 0), week 44
Change From Baseline in Number of Participants With Antihypertensive Medication (Decrease, No Change, Increase)
Change from baseline in number of participants in antihypertensive medication (decrease, no change, increase) at baseline (week 0) to week 44 are presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
Time frame: Baseline (week 0), week 44
Change From Baseline in Number of Participants With Lipid-Lowering Medication (Decrease, No Change, Increase)
Change from baseline in number of participants in lipid-lowering medication (decrease, no change, increase) at baseline (week 0) to week 44 are presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
Time frame: Baseline (week 0), week 44
Change From Baseline in Number of Participants With Concomitant Oral Antidiabetic Medication (Decrease, No Change, Increase) in Participants With No T2D at Baseline
Change from basline in number of participants with concomitant oral antidiabetic medication (decrease, no change, increase) at baseline (week 0) to week 44 are presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
Time frame: Baseline (week 0), week 44
Change From Baseline in Number of Participants in Fatty Liver Index (FLI) Score Category
Change from baseline in number of participants in fatty liver index (FLI) at baseline (week 0) to week 44 are presented. The fatty liver index is based on an algorithm including body mass index, waist circumference, triglycerides and gamma-glutamyl-transferase. The FLI scores less than (\<) 30 indicates no hepatic steatosis (no fatty liver), FLI greater than or equal to (\>=) 30 to less than (\<) 60 indicates intermediate status of hepatic steatosis and \>=60 indicates severe/worse hepatic steatosis. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
Time frame: Baseline (week 0), week 44
Number of Participants Who From Randomization Permanently Discontinued Randomized Trial Product
Number of participants who permanently discontinued randomized trial product from baseline (week 0) to week 44 are presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
Time frame: Baseline (week 0), week 44
Time to Permanent Discontinuation of Randomized Trial Product (Weeks)
Time to permanent discontinuation of randomised trial product from baseline (week 0) to week 44 is reported. Participants who permanently discontinued the randomised trial product during the in-trial observation period were only included in the analysis. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to date of last contact with trial site (week 51).
Time frame: Baseline (week 0), week 44
Number of Treatment Emergent Adverse Events (TEAEs)
An adverse event (AE) defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a product, whether or not considered related to the product. All AEs mentioned are treatment emergent adverse events (TEAE) defined as an event with onset during the on-treatment observation period. On-treatment observation period: the interval from the date of first trial product administration (week 0) to the date of last trial product administration (week 44) plus a 7 week follow-up period and excluding any off-treatment time intervals. Off-treatment time interval: time period with at least two consecutive missed doses.
Time frame: Baseline (week 0), week 51
Number of Serious Adverse Events (SAEs)
A serious adverse event (SAE) is defined as any untoward medical occurrence that at any dose results in death, or is life-threatening, or requires inpatient hospitalization or causes prolongation of existing hospitalization results in persistent or significant disability/incapacity, or may have caused a congenital anomaly/birth defect, or requires intervention to prevent permanent impairment or damage. SAE results occurred from week 0 to week 51 is presented based on the on-treatment observation, which was defined as the interval from the date of first trial product administration (week 0) to the date of last trial product administration (week 44) plus a 7 week follow-up period and excluding any off-treatment time intervals. Off-treatment time interval: time period with at least two consecutive missed doses.
Time frame: Baseline (week 0), week 51
Number of Treatment Emergent Severe or Blood Glucose (BG) Confirmed Symptomatic Hypoglycaemia Episodes (Yes/No) in Participants With T2D at Week 0
Hypoglycaemic episodes with onset during on-treatment observation period were considered treatment-emergent. Number of treatment emergent severe or BG confirmed symptomatic hypoglycaemia episodes in participants with T2D at week 0 with onset during on-treatment observation period were presented.
Time frame: Baseline (week 0), week 51
Change From Baseline in Pulse
Change in pulse from baseline (week 0) to week 44 is presented. The outcome measure was evaluated based on the data from on-treatment observation period, which was defined as the interval from the date of first trial product administration (week 0) to the date of last trial product administration (week 44) plus a 7 week follow-up period and excluding any off-treatment time intervals.
Time frame: Baseline (week 0), week 44
Change From Baseline in Amylase: Ratio to Baseline
Change in amylase measured in units/liter (U/L) from baseline (week 0) to week 44 is presented as ratio to baseline. The outcome measure was evaluated based on the data from on-treatment observation period, which was defined as the interval from the date of first trial product administration (week 0) to the date of last trial product administration (week 44) plus a 7 week follow-up period and excluding any off-treatment time intervals.
Time frame: Baseline (week 0), week 44
Change From Baseline in Lipase: Ratio to Baseline
Change in lipase measured in units/liter (U/L) from baseline (week 0) to week 44 is presented as ratio to baseline. The outcome measure was evaluated based on the data from on-treatment observation period, which was defined as the interval from the date of first trial product administration (week 0) to the date of last trial product administration (week 44) plus a 7 week follow-up period and excluding any off-treatment time intervals.
Time frame: Baseline (week 0), week 44
Change From Baseline in Calcitonin: Ratio to Baseline
Change in calcitonin measured in units/liter (U/L) from baseline (week 0) to week 44 is presented as ratio to baseline. The outcome measure was evaluated based on the data from on-treatment observation period, which was defined as the interval from the date of first trial product administration (week 0) to the date of last trial product administration (week 44) plus a 7 week follow-up period and excluding any off-treatment time intervals.
Time frame: Baseline (week 0), week 44
The trial was conducted at 28 sites in 3 countries as follows (all sites screened and randomized): Region China (includes China mainland and Hong Kong) China mainland (23 sites) and Hong Kong (1 site), Brazil (2 sites) and South Korea (2 sites).
| Milestone | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Started | 249 | 126 |
| Full analysis set (fas) | 249 | 126 |
| Safety analysis set (sas) | 249 | 126 |
| Treated | 249 | 126 |
| Completed | 244 | 121 |
| Not completed | 5 | 5 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Withdrawal by subject | 4 | 4 |
Change from baseline at week 0 to week 44 in body weight (%) is presented.The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
| Percentage change | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Change From Baseline in Body Weight (Percentage [%]) | -12.5 ± 7.4 | -3.6 ± 5.9 |
Number of participants who achieved \>=5% weight reduction at week 44 for in-trial observation period is presented.In the reported data, 'Yes' infers the number of participants who have achieved greater than or equal to 5% weight reduction, whereas 'No' infers the number of participants who have not achieved greater than or equal to 5% weight reduction. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
| Participants | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Yes | 203 | 36 |
| No | 35 | 80 |
Number of participants who achieved \>=10% weight reduction at week 44 for in-trial observation period is presented. In the reported data, 'Yes' infers the number of participants who have achieved greater than or equal to 10% weight reduction, whereas 'No' infers the number of participants who have not achieved greater than or equal to 10% weight reduction. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
| Participants | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Yes | 151 | 12 |
| No | 87 | 104 |
Number of participants who achieved \>=15% weight reduction at week 44 for in-trial observation period is presented. In the reported data, 'Yes' infers the number of participants who have achieved greater than or equal to 15% weight reduction, whereas 'No' infers the number of participants who have not achieved greater than or equal to 15% weight reduction. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
| Participants | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Yes | 82 | 7 |
| No | 156 | 109 |
Change in waist circumference from baseline (week 0) to week 44 is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomization (week 0) to last trial-related participant-site contact (week 51).
| Centimeter (cm) | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Change From Baseline in Waist Circumference | -11.1 ± 7.2 | -3.8 ± 5.8 |
Change in body weight from baseline (week 0) to week 44 is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
| Kilogram (kg) | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Change From Baseline in Body Weight (Kilogram [kg]) | -11.9 ± 7.3 | -3.4 ± 6.0 |
Change in BMI from baseline (week 0) to week 44 is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
| Kilograms per square meter (kg/m^2) | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Change From Baseline in Body Mass Index (BMI) | -4.3 ± 2.6 | -1.2 ± 2.1 |
Number of participants who achieved \>=20% weight reduction at week 44 for in-trial observation period is presented. In the reported data, 'Yes' infers the number of participants who have achieved greater than or equal to 20% weight reduction, whereas 'No' infers the number of participants who have not achieved greater than or equal to 20% weight reduction. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
| Participants | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Yes | 34 | 2 |
| No | 204 | 114 |
Change in systolic blood pressure from baseline (week 0) to week 44 is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
| Millimeters of mercury (mmHg) | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Change From Baseline in Systolic Blood Pressure | -7 ± 12 | -2 ± 12 |
SF-36 is a 36-item participants-reported survey of participants health that measures the partici-pants overall health-related quality of life (HRQoL). SF-36 questionnaire measured 8 domains of functional health and well-being as well as 2 component summary scores (physical component summary and mental component summary). This outcome measure shows results for 'physical functioning domain'. Physical function domain score ranges from 0 to 100, with higher values indicating better functional health and well-being. Change from baseline (week 0) in the domain scores were evaluated at week 44. These outcome measures were evaluated based on data from in-trial observation period which is the uninterrupted time interval from (week 0) to (week 51).
| Score on a scale | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Change From Baseline in Short Form-36 (SF-36) - Physical Functioning Score | 1.3 ± 4.7 | 0.2 ± 5.7 |
The Impact of Weight on Quality of Life Clinical Trials Version (IWQOL-Lite-CT) is designed to assess the impact of changes in weight on participants quality of life within the context of clinical trials. IWQOL-Lite-CT is a 20-item questionnaire-based instrument used to assess the impact of body weight changes on participants overall health-related quality of life (HRQoL). All IWQOL-Lite-CT composite and physical function domain scores range from 0 to 100, with higher scores reflecting better levels of functioning. This outcome measure shows results for 'physical function domain'. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomization (week 0) to last trial-related participant-site contact (week 51).
| Score on a scale | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Change From Baseline in Impact of Weight on Quality of Life-Lite for Clinical Trials (IWQOL-Lite for CT) - Physical Function Domain (5-items) Score | 8.0 ± 16.4 | 2.3 ± 18.5 |
Change in glycosylated haemoglobin (HbA1c) (%) from baseline (week 0) to week 44 is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
| Percentage of HbA1c | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Change From Baseline in Glycosylated Haemoglobin (HbA1c) (Percentage [%]) | -0.8 ± 0.8 | -0.1 ± 0.8 |
Change in HbA1c (mmol/mol) from baseline (week 0) to week 44 is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
| Millimoles per mole (mmol/mol) | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Change From Baseline in HbA1c (Millimoles Per Mole [mmol/Mol]) | -8.9 ± 9.2 | -1.3 ± 8.3 |
Change in fasting plasma glucose (mg/dL) from baseline (week 0) to week 44 is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
| Milligrams per deciliter (mg/dL) | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) (Milligrams Per Deciliter [mg/dL]) | -18.9 ± 25.3 | -1.1 ± 18.7 |
Change in FPG (mmol/L) from baseline (week 0) to week 44 is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
| Millimoles per litre (mmol/L) | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Change From Baseline in FPG (Millimoles Per Liter [mmol/L]) | -1.1 ± 1.4 | -0.1 ± 1.0 |
Change in fasting serum insulin measured as milli-international units per milliliter (mIU/mL) from baseline (week 0) to week 44 is presented as ratio to baseline. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
| Ratio of fasting serum insulin | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Change From Baseline in Fasting Serum Insulin: Ratio to Baseline | 0.76 ± 57.3 | 0.98 ± 62.9 |
Change in diastolic blood pressure from baseline (week 0) to week 44 is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
| mmHg | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Change From Baseline in Diastolic Blood Pressure | -4 ± 9 | -1 ± 9 |
Change in total cholesterol measured as milligrams per deciliter (mg/dL) from baseline (week 0) to week 44 is presented as ratio to baseline. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
| Ratio of total cholesterol | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Change From Baseline in Total Cholesterol: Ratio to Baseline | 0.94 ± 17.5 | 1.04 ± 17.5 |
Change in HDL measured as milligrams per deciliter (mg/dL) from baseline (week 0) to week 44 is presented as ratio to baseline. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
| Ratio of HDL | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Change From Baseline in High-Density Lipoproteins (HDL)-Ratio to Baseline | 1.05 ± 15.5 | 1.08 ± 16.6 |
Change in LDL measured as milligrams per deciliter (mg/dL) from baseline (week 0) to week 44 is presented as ratio to baseline. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
| Ratio of LDL | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Change From Baseline in Low-Density Lipoproteins (LDL)-Ratio to Baseline | 0.97 ± 33.0 | 1.04 ± 29.0 |
Change in VLDL measured as milligrams per deciliter (mg/dL) from baseline (week 0) to week 44 is presented as ratio to baseline. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
| Ratio of VLDL | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Change From Baseline in Very Low-Density Lipoproteins (VLDL)-Ratio to Baseline | 0.71 ± 45.3 | 0.96 ± 44.3 |
Change in free fatty acids measured as milligrams per deciliter (mg/dL) from baseline (week 0) to week 44 is presented as ratio to baseline. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
| Ratio of free fatty acids | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Change From Baseline in Free Fatty Acids-Ratio to Baseline | 0.91 ± 66.9 | 1.05 ± 69.7 |
Change in triglycerides measured as milligrams per deciliter (mg/dL) from baseline (week 0) to week 44 is presented as ratio to baseline. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
| Ratio of triglycerides | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Change From Baseline in Triglycerides-Ratio to Baseline | 0.71 ± 50.2 | 0.96 ± 52.6 |
SF-36 is a 36-item participant-reported survey of health that measures the overall HRQoL. SF-36 questionnaire measured 8 domains of functional health and well-being as well as 2 component summary scores (physical and mental component summary). This outcome measure shows results for all domains (except physical functioning) and 2 component summary scores. The score ranges from 0 to 100, with higher values indicating better functional health and well-being. Change from baseline week 0 in domain and component summary scores were evaluated at week 44 based on data from in-trial observation period which is uninterrupted time interval from (week 0) to (week 51).
| Score on a scale | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Role-Physical | 0.5 ± 5.1 | -0.8 ± 6.3 |
| Bodily Pain | -0.3 ± 7.1 | -1.2 ± 7.3 |
| General Health | 3.2 ± 7.6 | 1.6 ± 7.6 |
| Vitality | 0.3 ± 7.8 | -1.1 ± 6.7 |
| Social Functioning | -0.5 ± 5.6 | -0.5 ± 5.0 |
| Role-Emotional | 0.5 ± 7.0 | -0.9 ± 5.9 |
| Mental Health | -0.1 ± 7.4 | -1.8 ± 7.1 |
| Physical component summary | 1.4 ± 5.2 | 0.4 ± 5.5 |
| Mental component summary | -0.3 ± 7.1 | -1.5 ± 6.1 |
The Impact of Weight on Quality of Life Clinical Trials Version (IWQOL-Lite-CT) is designed to assess the impact of changes in weight on participants quality of life within the context of clinical trials. IWQOL-Lite-CT is a 20-item questionnaire-based instrument used to assess the impact of body weight changes on participants overall health-related quality of life (HRQoL). All IWQOL-Lite-CT composite scores for physical domain score, psychosocial domain score and total score ranges from 0 to 100, with higher scores reflecting better levels of functioning. This outcome measure shows results for 'physical and psychosocial domains, and for total'. The outcome measure was evaluated based on the data from in-trial observation period which is the uninterrupted time interval from start of randomization (week 0) to last trial-related participant-site contact (week 51).
| Score on a scale | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Physical | 7.2 ± 16.3 | 2.0 ± 18.3 |
| Psychosocial | 12.0 ± 17.3 | 4.8 ± 17.4 |
| Total | 10.3 ± 15.4 | 3.8 ± 16.2 |
The number of participants experiencing a meaningful within participant improvement in SF-36 Physical function after 44 weeks was determined based on 3.7 threshold. The threshold of 3.7 is specific for overweight or obese population included in the study and calculated using participant global rating anchor questionnaires to reflect participants own perspective based on Food and Drug Administration (FDA) recommendations. In the reported data, "Yes" infers the number of participants who have achieved an improvement in score greater than or equal to the threshold and "No" infers number of participants who have not achieved an improvement in score greater than or equal to the threshold. The outcome measure was evaluated based on in-trial observation period which is the uninterrupted time interval from start of randomization (week 0) to last trial-related participant-site contact (week 51).
| Participants | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Yes | 69 | 27 |
| No | 168 | 89 |
The number of participants experiencing a meaningful within participant improvement in IWQOL-Lite-CT physical function after 44 weeks was determined based on thresholds of 14.6. The threshold of 14.6 is specific for the population with overweight or obesity included in the study and calculated using patient global rating anchor questionnaires to reflect participants own perspective based on FDA recommendations. In the reported data, "Yes" infers the number of participants who have achieved an improvement in score greater than or equal to the threshold and "No" infers the number of participants who have not achieved an improvement in score greater than or equal to the threshold. The outcome measure was evaluated based on in-trial observation period which is the uninterrupted time interval from start of randomization (week 0) to last trial-related participant-site contact (week 51).
| Participants | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Yes | 83 | 22 |
| No | 153 | 93 |
Number of participants with T2D who achieved HbA1c \< 7% (53 mmol/mol) at week 44 is presented. In the reported data, "Yes" infers the number of participants who have achieved HbA1c values less than the 7% and "No" infers the number of participants who have not achieved HbA1c values less than the 7%. The outcome measure was evaluated based on the data from in-trial observation period which was defined as the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
| Participants | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Yes | 57 | 8 |
| No | 5 | 20 |
Number of participants with T2D who achieved HbA1c \<= 6.5% (48 mmol/mol) at week 44 is presented. In the reported data, "Yes" infers the number of participants who have achieved HbA1c values less than or equal to 6.5% and "No" infers the number of participants who have not achieved HbA1c values less than or equal to 6.5%. The outcome measure was evaluated based on the data from in-trial observation period which was defined as the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
| Participants | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Yes | 51 | 4 |
| No | 11 | 24 |
Change from baseline in number of participants in glycaemic categories (normo-glycaemia, pre-diabetes and type 2 diabetes) at baseline (week 0) to week 44 are presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
| Participants | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Normo-glycaemia | 158 | 53 |
| Pre-diabetes | 15 | 29 |
| Diabetes | 0 | 2 |
Change from baseline in number of participants in antihypertensive medication (decrease, no change, increase) at baseline (week 0) to week 44 are presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
| Participants | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Decreased | 8 | 2 |
| No change | 57 | 23 |
| Increased | 9 | 4 |
Change from baseline in number of participants in lipid-lowering medication (decrease, no change, increase) at baseline (week 0) to week 44 are presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
| Participants | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Decreased | 3 | 1 |
| No change | 31 | 13 |
| Increased | 1 | 4 |
Change from basline in number of participants with concomitant oral antidiabetic medication (decrease, no change, increase) at baseline (week 0) to week 44 are presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
| Participants | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Decreased | 16 | 2 |
| No change | 35 | 16 |
| Increased | 1 | 6 |
Change from baseline in number of participants in fatty liver index (FLI) at baseline (week 0) to week 44 are presented. The fatty liver index is based on an algorithm including body mass index, waist circumference, triglycerides and gamma-glutamyl-transferase. The FLI scores less than (\<) 30 indicates no hepatic steatosis (no fatty liver), FLI greater than or equal to (\>=) 30 to less than (\<) 60 indicates intermediate status of hepatic steatosis and \>=60 indicates severe/worse hepatic steatosis. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
| Participants | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| <30 | 67 | 8 |
| 30<= to <60 | 62 | 17 |
| >=60 | 107 | 88 |
Number of participants who permanently discontinued randomized trial product from baseline (week 0) to week 44 are presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to last trial-related participant-site contact (week 51).
| Participants | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Number of Participants Who From Randomization Permanently Discontinued Randomized Trial Product | 18 | 16 |
Time to permanent discontinuation of randomised trial product from baseline (week 0) to week 44 is reported. Participants who permanently discontinued the randomised trial product during the in-trial observation period were only included in the analysis. In-trial observation period: the uninterrupted time interval from the start of randomization (week 0) to date of last contact with trial site (week 51).
| Weeks | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Time to Permanent Discontinuation of Randomized Trial Product (Weeks) | 16.7 (5.4 to 43.1) | 18.8 (3.0 to 43.3) |
An adverse event (AE) defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a product, whether or not considered related to the product. All AEs mentioned are treatment emergent adverse events (TEAE) defined as an event with onset during the on-treatment observation period. On-treatment observation period: the interval from the date of first trial product administration (week 0) to the date of last trial product administration (week 44) plus a 7 week follow-up period and excluding any off-treatment time intervals. Off-treatment time interval: time period with at least two consecutive missed doses.
| Events | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Number of Treatment Emergent Adverse Events (TEAEs) | 1122 | 415 |
A serious adverse event (SAE) is defined as any untoward medical occurrence that at any dose results in death, or is life-threatening, or requires inpatient hospitalization or causes prolongation of existing hospitalization results in persistent or significant disability/incapacity, or may have caused a congenital anomaly/birth defect, or requires intervention to prevent permanent impairment or damage. SAE results occurred from week 0 to week 51 is presented based on the on-treatment observation, which was defined as the interval from the date of first trial product administration (week 0) to the date of last trial product administration (week 44) plus a 7 week follow-up period and excluding any off-treatment time intervals. Off-treatment time interval: time period with at least two consecutive missed doses.
| Events | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Number of Serious Adverse Events (SAEs) | 14 | 8 |
Hypoglycaemic episodes with onset during on-treatment observation period were considered treatment-emergent. Number of treatment emergent severe or BG confirmed symptomatic hypoglycaemia episodes in participants with T2D at week 0 with onset during on-treatment observation period were presented.
| Episodes | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Number of Treatment Emergent Severe or Blood Glucose (BG) Confirmed Symptomatic Hypoglycaemia Episodes (Yes/No) in Participants With T2D at Week 0 | 2 | 1 |
Change in pulse from baseline (week 0) to week 44 is presented. The outcome measure was evaluated based on the data from on-treatment observation period, which was defined as the interval from the date of first trial product administration (week 0) to the date of last trial product administration (week 44) plus a 7 week follow-up period and excluding any off-treatment time intervals.
| Beats per minute (bpm) | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Change From Baseline in Pulse | 4 ± 10 | 1 ± 10 |
Change in amylase measured in units/liter (U/L) from baseline (week 0) to week 44 is presented as ratio to baseline. The outcome measure was evaluated based on the data from on-treatment observation period, which was defined as the interval from the date of first trial product administration (week 0) to the date of last trial product administration (week 44) plus a 7 week follow-up period and excluding any off-treatment time intervals.
| Ratio of amylase | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Change From Baseline in Amylase: Ratio to Baseline | 1.19 ± 19.4 | 1.08 ± 20.5 |
Change in lipase measured in units/liter (U/L) from baseline (week 0) to week 44 is presented as ratio to baseline. The outcome measure was evaluated based on the data from on-treatment observation period, which was defined as the interval from the date of first trial product administration (week 0) to the date of last trial product administration (week 44) plus a 7 week follow-up period and excluding any off-treatment time intervals.
| Ratio of lipase | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Change From Baseline in Lipase: Ratio to Baseline | 1.54 ± 41.8 | 1.08 ± 37.8 |
Change in calcitonin measured in units/liter (U/L) from baseline (week 0) to week 44 is presented as ratio to baseline. The outcome measure was evaluated based on the data from on-treatment observation period, which was defined as the interval from the date of first trial product administration (week 0) to the date of last trial product administration (week 44) plus a 7 week follow-up period and excluding any off-treatment time intervals.
| Ratio of calcitonin | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Change From Baseline in Calcitonin: Ratio to Baseline | 1.04 ± 37.0 | 0.92 ± 39.4 |
Collected over Week 0 to week 51. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sema 2.4 mg | 0/249 (0%) | 14/249 (5.6%) | 180/249 (72.3%) |
| Placebo | 0/126 (0%) | 8/126 (6.3%) | 57/126 (45.2%) |
| Event | Sema 2.4 mg | Placebo |
|---|---|---|
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 0/249 | 2/126 |
| Upper respiratory tract infectionInfections and infestations | 2/249 | 0/126 |
| Bladder cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/249 | 1/126 |
| Gastric ulcerGastrointestinal disorders | 0/249 | 1/126 |
| GastroenteritisInfections and infestations | 1/249 | 1/126 |
| Meniscus injuryInjury, poisoning and procedural complications | 0/249 | 1/126 |
| Metabolic syndromeMetabolism and nutrition disorders | 0/249 | 1/126 |
| PyrexiaGeneral disorders | 0/249 | 1/126 |
| Abdominal pain upperGastrointestinal disorders | 1/249 | 0/126 |
| Anal abscessInfections and infestations | 1/249 | 0/126 |
| Event | Sema 2.4 mg | Placebo |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 65/249 | 13/126 |
| NauseaGastrointestinal disorders | 60/249 | 9/126 |
| Upper respiratory tract infectionInfections and infestations | 51/249 | 26/126 |
| Decreased appetiteMetabolism and nutrition disorders | 43/249 | 5/126 |
| ConstipationGastrointestinal disorders | 29/249 | 7/126 |
| Abdominal distensionGastrointestinal disorders | 25/249 | 1/126 |
| VomitingGastrointestinal disorders | 21/249 | 0/126 |
| Abdominal pain upperGastrointestinal disorders | 15/249 | 4/126 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 15/249 | 3/126 |
| COVID-19Infections and infestations | 15/249 | 5/126 |
Full analysis set (FAS) included all randomized participants.
| Age, Continuous(Years) | Semaglutide 2.4 mg | Placebo | Total |
|---|---|---|---|
| Mean | 41 ± 11 | 40 ± 11 | 41 ± 11 |
| Sex: Female, Male(Participants) | Semaglutide 2.4 mg | Placebo | Total |
|---|---|---|---|
| Female | 111 | 59 | 170 |
| Male | 138 | 67 | 205 |
| Ethnicity (NIH/OMB)(Participants) | Semaglutide 2.4 mg | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 26 | 11 | 37 |
| Not Hispanic or Latino | 223 | 115 | 338 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Semaglutide 2.4 mg | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 225 | 115 | 340 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 2 | 4 |
| White | 22 | 9 | 31 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
Ran from Dec 2020 to primary completion in Aug 2022, 20 months.
Results were first posted in Nov 2024, 2 years 3 months after primary completion.
Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 20 months is close to that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Semaglutide